arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Cabaletta Bio, Inc.

CABA
$1.26 ▼ -0.16 (-11.27%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
35 Visible periods
19 Metrics
Peer-ranked Benchmarks
Price Chart
17
Health
Poor
Bearish
auto_awesome

Analytical Summary

Cabaletta Bio, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $190.5M
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC -19.5% ↗
FCF / Share $-0.27 ↗
Trailing P/E —
Price / Book 0.9x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

35-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-43.52M
↓ -21.1% —
FCF / Share Free cash flow per share
$-0.27
↑ +44.4% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
5
Financial Health ↑
14
Cash Quality →
53

Dividend History

Dividend / share · sourced from SEC filings
$0.00 Latest / share

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 9 years · 35 quarters